DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Information source: University Hospital Case Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Patient Noncompliance

Intervention: haloperidol decanoate (Drug); haloperidol (Drug); Customized Adherence Enhancement (Behavioral)

Phase: N/A

Status: Completed

Sponsored by: University Hospital Case Medical Center

Official(s) and/or principal investigator(s):
Martha Sajatovic, MD, Principal Investigator, Affiliation: University Hospital Case Medical Center

Summary

Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%. Inadequate adherence is associated with poor outcomes such as relapse, homelessness, hospitalization, and increased health care costs. Studies have shown a direct correlation between non-adherence and rates of relapse in schizophrenia; on average, non-adherent patients have a risk of relapse that is 3. 7 times greater than their adherent counterparts. A major obstacle to good outcomes in the maintenance treatment of patients with severe mental illness is difficulty with medication routines on an on-going basis. For this reason, long-acting injectable antipsychotic medication is a particularly attractive treatment option for populations with schizophrenia and schizoaffective disorder, although it is unlikely that medication treatment alone is likely to modify long-term attitudes and behaviors. This prospective study is a pilot analysis of a combined approach which merges a psychosocial intervention to optimize treatment attitudes towards psychotropic medication (CAE) and long-acting injectable antipsychotic medication (L) in recently homeless individuals with schizophrenia or schizoaffective disorder who are known to have on-going difficulties with treatment non-adherence. It is expected that this combined approach (CAE-L) will improve illness outcomes among the most vulnerable of populations with schizophrenia or schizoaffective disorder.

Clinical Details

Official title: A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome:

Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks

Change From Baseline in Treatment Adherence Score as Measured at 25 Weeks

Change From Baseline in Adherence Attitude Score as Measured by the Drug Attitude Inventory (DAI) at 25 Weeks

Change From Baseline in Treatment Adherence Behavior Score as Measured by the Morisky Medication Rating Scale at 25 Weeks

Change From Baseline in Adherence Attitude Score as Measured by the Attitude Toward Medication Questionnaire (AMQ) at 25 Weeks

Secondary outcome:

Frequency of Health Resource Use Throughout Months 10, 11, and 12

Change in Serious Mental Illness Severity Score as Measured by the Brief Psychiatric Rating Scale (BPRS) at 25 Weeks

Change in Global Psychopathology as Measured by the Clinical Global Impressions (CGI) at 25 Weeks

Change in Social and Occupational Functioning Scale (SOFAS) as Measured at 25 Weeks

Treatment Satisfaction as Measured by the Participant Acceptability and Satisfaction Questionnaire at 25 Weeks

Change in Schizophrenia and Schizoaffective Disorder Symptom Severity Scale as Measured by the Positive and Negative Syndrome Scale (PANSS) at 25 Weeks

Frequency of Health Resource Use in the Past 3 Months as Measured at 25 Weeks

Global Psychopathology as Measured by the Clinical Global Impressions (CGI) at 12 Months

Change in Social and Occupational Functioning Scale (SOFAS) as Measured at 12 Months

Treatment Satisfaction as Measured by the Participant Acceptability and Satisfaction Questionnaire at 12 Months

Days Homeless Out of the Previous 6 Months as Measured at 12 Months

Treatment Adherence Score as Measured at 12 Months

Adherence Attitude Score as Measured by the Drug Attitude Inventory (DAI) at 12 Months

Treatment Adherence Behavior Score as Measured by the Morisky Medication Rating Scale at 12 Months

Adherence Attitude Score as Measured by the Attitude Toward Medication Questionnaire (AMQ) at 12 Months

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Individuals age 18 years old and older with schizophrenia or schizoaffective disorder as confirmed by the Mini International Psychiatric Inventory (MINI). 2. Individuals who are currently or have been recently homeless (within the past 12 months) as per the official federal definition of homelessness. 3. Known to have medication treatment adherence (20% or more missed medications in past week or past month) problems as identified by the Treatment Routines Questionnaire patient or clinician versions (TRQ-P/TRQ-C). 4. Ability to be rated on psychiatric rating scales. 5. Willingness to take long-acting injectable medication. 6. Currently receiving treatment at a Community Mental Health Clinic (CMHC) or another mental health treatment provider who is able to provide continuity of care during and after study participation. 7. Able to provide written, informed consent to study participation. 8. Women of child-bearing potential must be utilizing reliable, medically-accepted methods of birth control. Exclusion Criteria: 1. Known resistance or intolerance to haloperidol or haloperidol decanoate. 2. Medical contraindication to haloperidol or haloperidol decanoate. 3. Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment. 4. Prior or current treatment with clozapine. 5. Concurrent medical condition or psychiatric illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial. 6. Current substance dependence. 7. High risk of harm to self or others. 8. Female who is currently pregnant or breastfeeding. 9. Individual who is already in permanent and supported housing that includes comprehensive mental health services (e. g. Housing First).

Locations and Contacts

University Hosptials, Cleveland, Ohio 44106, United States
Additional Information

Starting date: June 2010
Last updated: December 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017